Despite effective weight loss, obese people often face challenges in maintaining weight after returning to a normal diet post-intervention
Maps failed to load Sorry, unable to load the Maps API
You may need regular tests such as kidney function and blood glucose levels to check that the medicine is working properly.USES OF ALOJA TABLET Treatment of Type 2 diabetes mellitus Lowering blood glucose levels is an essential part of managing diabetes
Tnh trng thiu m, thiu nc c th khin da bn tr nn sn si, km mn mng, nhanh lo ha v mng manh hn

Phase 2 Trial Design Participants: 338 adults with obesity (BMI 30) or overweight with comorbidities (BMI 27), without diabetes Duration: 48 weeks Dosing groups: Placebo, 1mg, 4mg, 8mg, or 12mg weekly (with gradual dose escalation over 20-24 weeks) Primary endpoint: Percentage change in body weight from baseline Beyond Weight Loss: Metabolic Improvements Beyond weight loss, the 12mg dose also improved several cardiometabolic markers: Blood pressure: Systolic BP decreased by 7.4 mmHg (clinically significant reduction) Lipids: Triglycerides fell 30%, HDL cholesterol increased 8% Glucose control: HbA1c decreased 0.4% even in participants without diabetes Liver health: Markers of fatty liver disease (ALT, AST) improved significantly Inflammation: C-reactive protein (CRP) decreased, indicating reduced systemic inflammation What this means: Retatrutide appears to improve the metabolic dysfunction behind obesity-related diseases, not just the weight itself